The nation of Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (£272m) over five years due to the United States' insistence on confidential biological samples.
This rejection came to light following a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesperson later stated that the United States was requesting health data for research and commercial gain while refused to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more negotiations to secure a deal suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a high court suspended a related deal with the US after concerns were filed about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance openness and responsibility.
According to reports, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our people should a new pandemic emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending structures already set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This framework is intended to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation might be designed in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body said it acknowledged the official position, but urged that talks need to persist given that a large portion of the country's Aids initiatives depended on international support.
"Where technical issues arise, including those involving data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it said.
This impasse highlights the complex debate between accepting vital international aid and safeguarding national sovereignty in an increasingly interconnected world.